{"id":"W3215508843","doi":"10.1093/neuonc/noab196.242","title":"CTNI-17. A PHASE 1 WITH DOSE EXPANSION/PHASE 2 STUDY OF SELINEXOR IN COMBINATION WITH STANDARD OF CARE THERAPY FOR NEWLY DIAGNOSED OR RECURRENT GLIOBLASTOMA","year":2021,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Nuclear Structure and Function","field":"Biochemistry, Genetics and Molecular Biology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Temozolomide; Clinical endpoint; Medicine; Oncology; Bevacizumab; Phases of clinical research; Internal medicine; Radiation therapy; Clinical trial; Cancer research; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00008166507,0.0001544783,0.0003517526,0.00007685934,0.00003752625,0.000006012022,0.00008739556,0.0001242196,0.00002480541],"category_scores_gemma":[0.00008492659,0.0001017196,0.00004421155,0.0002158631,0.00005794425,0.00000642421,0.00003134146,0.0001015864,1.421589e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003963522,"about_ca_system_score_gemma":0.0004075204,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000115546,"about_ca_topic_score_gemma":0.001581079,"domain_scores_codex":[0.9988918,0.0001523995,0.0002919539,0.0003638039,0.0001455507,0.0001545158],"domain_scores_gemma":[0.9989387,0.00007553933,0.0002051549,0.0002773413,0.0004545198,0.00004868451],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1268556,0.004699023,0.000786669,0.00006500915,0.00009172052,0.0001522572,0.00287138,0.0001767161,0.7196186,0.000009545147,0.0008310379,0.1438425],"study_design_scores_gemma":[0.09487385,0.3911201,0.0006328103,0.00004057436,0.00009229674,0.00006917606,0.008261406,0.00009687859,0.4436093,0.00001046885,0.06096675,0.0002263995],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9979785,0.0001865119,0.0004470623,0.0001346775,0.000162972,0.0009805205,0.00006985402,0.000007837951,0.00003207232],"genre_scores_gemma":[0.9985173,0.0001315909,0.0008391736,0.0001745514,0.00006545782,0.00010918,0.0001213253,0.00002753359,0.00001386052],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3864211,"threshold_uncertainty_score":0.4148003,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01334965007866061,"score_gpt":0.3127865269656032,"score_spread":0.2994368768869426,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}